NCT03462173View on ClinicalTrials.gov

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 3, 2014

Primary Completion Date

January 30, 2015

Study Completion Date

January 22, 2016

Conditions
Chronic Hepatitis c
Interventions
DRUG

yimitasvir

Capsule administered orally once daily

DRUG

placebo

Matching Placebo Capsule

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03462173 - The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects | Biotech Hunter | Biotech Hunter